Sanofi SA has selected KT-485 (SAR-447971) to advance into clinical studies under its IRAK-4 partnership with Kymera Therapeutics Inc.

Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to ...

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. As the number and size of lipid droplets (LDs) generally increase in hepatocytes during the early stages of ...

Formation Bio CEO Benjamine Liu joins 'Fast Money' as Formation comes in at #37 on the Disruptor 50 list. More for You. Melania Trump's visa questioned in congressional hearing.